Evidence map›Paper›PMID 38847271›Full record

ArticleOncology reports2024

[Corrigendum] Next‑generation sequencing analysis reveals that MTH‑3, a novel curcuminoid derivative, suppresses the invasion of MDA‑MB‑231 triple‑negative breast adenocarcinoma cells.

Yu-Jen Chiu, Fuu-Jen Tsai, Da-Tian Bau, Ling-Chu Chang, Min-Tsang Hsieh, Chi-Cheng Lu, Sheng-Chu Kuo, Jai-Sing Yang

Abstract readPublished Erratum
In one paragraph

Article in Oncology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Yu-Jen ChiuDivision of Plastic and Reconstructive Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei 11217, Taiwan, R.O.C.
Fuu-Jen TsaiHuman Genetic Center, China Medical University, Taichung 40402, Taiwan, R.O.C.
Da-Tian BauDepartment of Medical Research, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan, R.O.C.
Ling-Chu ChangChinese Medicinal Research and Development Center, China Medical University Hospital, Taichung 40402, Taiwan, R.O.C.
Min-Tsang HsiehChinese Medicinal Research and Development Center, China Medical University Hospital, Taichung 40402, Taiwan, R.O.C.
Chi-Cheng LuDepartment of Sport Performance, National Taiwan University of Sport, Taichung 40402, Taiwan, R.O.C.
Sheng-Chu KuoChinese Medicinal Research and Development Center, China Medical University Hospital, Taichung 40402, Taiwan, R.O.C.
Jai-Sing YangDepartment of Medical Research, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan, R.O.C.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Subsequently to the publication of the article, an interested reader drew to the authors' attention that, in Fig. 2A on p. 5, the 'Control  (24 h)' and 'MTH‑3 (1 μM; 24 h)' data panels contained partially overlapping data, such that they appeared to have been derived from the same original source. The authors have examined their original data, and realized that this error arose inadvertently as a consequence of having compiled this figure incorrectly. The revised version of Fig. 2, featuring the data from one of the repeated experiments in Fig. 2A, is shown below. The revised data shown for this figure do not affect the overall conclusions reported in the paper. The authors apologize to the Editor of

Indexed as

anti‑metastasiscurcuminoid derivativeMTH‑3next generation sequencing analysistriple‑negative breast cancer (TNBC)

Identifiers

PMID38847271
PMCPMC11170257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.